Novo Nordisk Dividends and Buybacks
Dividend criteria checks 4/6
Novo Nordisk is a dividend paying company with a current yield of 2.29% that is well covered by earnings.
Key information
2.3%
Dividend yield
0.8%
Buyback Yield
| Total Shareholder Yield | 3.1% |
| Future Dividend Yield | 3.4% |
| Dividend Growth | 12.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 48% |
Recent dividend and buyback updates
Recent updates
Novo Nordisk: The Time To Buy Has Come
Jun 10Novo Nordisk: Examining Tariff And Pricing Risks
Apr 26Novo Nordisk: A Price Too Low To Ignore
Apr 18Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Mar 30Novo Nordisk: CagriSema Disappoints Again
Mar 10Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Feb 20Novo Nordisk: Dips Like These Come Once Every Few Years
Feb 13
Novo Nordisk aims for a promising future with a fair value of 101.75
Revenue growth is expected to be driven by continued demand for GLP-1 drugs, especially Ozempic and Wegovy.Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Feb 05Novo Nordisk: Excellent Opportunity To Buy The Dip
Jan 15Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Jan 06Novo Nordisk Stock: A Rare Buying Opportunity
Dec 20Novo Nordisk: Just The Right Price (Rating Upgrade)
Dec 11Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Nov 25Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Nov 06Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Sep 10Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Stability and Growth of Payments
Fetching dividends data
Stable Dividend: NVO's dividend payments have been volatile in the past 10 years.
Growing Dividend: NVO's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Novo Nordisk Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NVO) | 2.3% |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (NVO) (up to 3 years) | 3.4% |
Notable Dividend: NVO's dividend (2.29%) is higher than the bottom 25% of dividend payers in the US market (1.58%).
High Dividend: NVO's dividend (2.29%) is low compared to the top 25% of dividend payers in the US market (4.74%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (48.5%), NVO's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (68.1%), NVO's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/16 23:24 |
| End of Day Share Price | 2025/06/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 71 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |